Cepharanthine trial

Clinicopathological study on the efficacy of Cepharanthine for preventing salivary gland destruction in Sjogren's syndrome patients - Cepharanthine trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

JPRN

Registry ID

JPRN-jRCTs061180072

Enrollment

Registered

2019-03-19

Start date

2011-08-11

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

SjS

Interventions

Cepharanthine (6 mg / day) administration

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Outpatient 20 years or older who meets the diagnostic criteria of Sjogren's syndrome

Exclusion criteria

Exclusion criteria: 1. History of hypersensitivity to cepharanthine 2. Serious ischemic heart disease 3. Bronchial asthma and chronic obstructive pulmonary disease 4. Blockade of gastrointestinal tract and bladder neck 5. Epilepsy 6. Parkinsonism or Parkinson's disease 7. Patients with iritis 8. Pregnant women, lactating women or possible pregnancy 9. Others inappropriate

Design outcomes

Primary

Measure	Time frame
To evaluate (1) salivary secretion improvement after taking cepharanthine (6 mg / day) compared with the first time in patients with Sjogren's syndrome.	—

Secondary

Measure	Time frame
(2) Improvement of CRP value. And in the histopathology (3) Improvement of lymphocyte infiltration, (4) Improvement of acinar structural destruction.	—

Contacts

Public ContactTomoko Yamanoi

Tokushima University

yamanoi.tomoko@tokushima-u.ac.jp+81-88-633-7352

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026